CMS’ Fourth COVID-19 Interim Final Rule with Comment Period includes additional payment for new COVID-19 treatments, price transparency requirements for COVID-19 diagnostic tests, and coverage for potential vaccines among other provisions.
The discovery of an overpayment raises serious questions about compliance requirements. Understand your organization’s reporting obligation and appropriate methods for determining overpayments.
